Abstract
This strategic report from Espicom puts the spotlight on current and future
drugs that will be used in the treatment of Type I and Type II diabetes,
providing industry and investors with a comprehensive overview of the market
in the medium term.
The withdrawal of Pfizer' s Exubera and safety concerns over the
thiazolidinediones has not reduced interest in this fast growing global
sector. New products, drug delivery technologies and therapeutic approaches
continue apace.
It is estimated that around 250 million people are living with diabetes today
and this number will increase to around 380 million by 2025.
Diabetes has become a major cause of premature illness and death in most
countries, mainly through the increased risk of cardiovascular disease. In
2005, an estimated 1.1 million people around the world died directly from
diabetes. The number of people whose death was recorded as heart disease or
kidney failure where diabetes was a contributory factor is, however,
considerably higher. Each year, diabetes related causes account for 3.8
million deaths; equivalent to one death every ten seconds and claiming the
lives of as many people as HIV/AIDS.
Key questions answered include:
- Which markets will see the most significant growth in diabetes incidence?
- What drug delivery approaches are showing promise and who is developing
them?
- What commercial impact are safety issues having on GSK' s Avandia?
- How did sanofi-aventis boost sales of Lantus in 2008?
- To what degree will Novartis' Galvus be able to compete with Merck' s
Januvia in the DPP-4 inhibitor battle?
........The rapidly increasing patient pool and high unmet clinical need will
translate into a continuing increase in revenue for several years to come.....
About the Author
The report has been researched and written by Espicom' s Senior Market Analyst,
Karen Holmes. Karen has over 12 years pharmaceutical and healthcare market
analysis experience.
| 
View Cart
